Clinical Trials Sponsored by Exeltis Turkey
Total 1230 results
-
Exeltis TurkeyMonitor CROCompletedTrichomonal Vaginitis | Bacterial Vaginosis | Candidal Vulvovaginitis | Mixed Vaginal InfectionsTurkey
-
Exeltis TurkeyMonitor CROActive, not recruiting
-
Ege UniversityExeltis Turkey; Monitor CROCompletedTrichomonal Vaginitis | Bacterial Vaginosis | Candidal Vulvovaginitis | Mixed Vaginal InfectionsTurkey
-
Ministry of Health, TurkeyTurk Telekomunikasyon A.Ş., Istanbul, TurkeyCompletedPrimary Prevention | Lifestyle Risk Reduction | Digital HealthTurkey
-
XeltisRecruitingEnd-stage Renal DiseaseSpain, Italy, Belgium, Latvia, Portugal, Germany, Greece, United Kingdom, Poland
-
XeltisEnrolling by invitationMulti Vessel Coronary Artery DiseaseBelgium, Lithuania
-
XeltisWithdrawnHeart Defects, CongenitalHungary, Malaysia, Poland, Slovakia
-
Inmunova S.A.ExeltisTerminatedHemolytic-Uremic Syndrome | Pediatric Kidney Disease | Bloody Diarrhea | STEC, UnspecifiedArgentina
-
XeltisActive, not recruitingEnd Stage Renal Disease | End Stage Renal Failure on DialysisItaly, Belgium, Latvia, Lithuania
-
XeltisEnrolling by invitationHeart Defect, CongenitalUnited States, Bulgaria, Malaysia, Poland
-
XeltisActive, not recruitingCongenital Heart DiseaseHungary, Malaysia, Poland
-
Exeltis FranceInsud PharmaCompleted
-
AstraZeneca TurkeyOptimum Contract Research Organization, TurkeyCompletedType 2 Diabetes MellitusTurkey
-
Xiromed LLCLaboratorios Liconsa; ExeltisCompleted
-
ExelixisActive, not recruitingHepatocellular CarcinomaUnited States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Georgia, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Philippines, ... and more
-
ExelixisActive, not recruitingRenal Cell Carcinoma | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Urothelial Carcinoma | Differentiated Thyroid Cancer | Gastroesophageal... and other conditionsUnited States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
ExelixisCompletedRenal Cell CarcinomaUnited States, Belgium, Spain, Taiwan, Canada, Germany, Korea, Republic of, France, Austria, Chile, Australia, Hungary, Russian Federation, Italy, Turkey, Netherlands, Sweden, United Kingdom, Czechia, Ireland, Slovakia, Argentina, D... and more
-
ExelixisTerminatedPain | Prostatic Neoplasms | Prostate Cancer | Castration Resistant Prostate CancerUnited States, Canada, Australia, United Kingdom, Ireland
-
ExelixisTerminatedProstatic Neoplasms | Prostate Cancer | Castration Resistant Prostate CancerUnited States
-
ExelixisCompletedHealthy | Hepatic ImpairmentUnited States
-
ExelixisCompletedHealthy | Renal ImpairmentUnited States
-
ExelixisRecruitingHead and Neck Squamous Cell CarcinomaUnited States
-
ExelixisRecruiting
-
ExelixisRecruitingNon-Clear Cell Renal Cell CarcinomaUnited States, Spain, Korea, Republic of, Italy, Australia, France, Argentina, Brazil, Chile, Czechia, Finland, Germany, Malaysia, Netherlands, Poland, Thailand
-
ExelixisRecruitingRenal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Metastatic Castration-resistant Prostate CancerUnited States, Poland, Spain, Switzerland, Austria, Australia, Belgium, Israel, Italy, New Zealand, France, Germany, United Kingdom
-
ExelixisRecruitingCervical Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor-positive Breast Cancer | SCCHN | Esophageal SCC | Tissue Factor-Expressing Solid TumorsUnited States, Spain, Australia, Belgium, France, Italy, Netherlands, United Kingdom, Korea, Republic of
-
ExelixisActive, not recruitingA Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (STELLAR-001)Renal Cell Carcinoma | Colorectal Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm MalignantUnited States, Australia, Belgium, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
ExelixisCompletedGlioblastoma MultiformeUnited States
-
ExelixisCompletedPain | Prostatic Neoplasms | Prostate Cancer | Castration Resistant Prostate CancerBelgium, France, Italy, Canada, United States, Germany, United Kingdom, Australia, Netherlands, Spain, Austria, Ireland, Puerto Rico, Sweden
-
ExelixisTerminated
-
ExelixisTerminatedLymphoma | CancerUnited States
-
ExelixisTerminatedLymphoma | CancerUnited States
-
ExelixisTerminated
-
ExelixisCompletedCancer | NSCLC | Solid TumorsJapan
-
ExelixisWithdrawnCancer | Breast Cancer | Non-small-cell Lung CancerUnited States
-
ExelixisCompletedAstrocytic TumorsUnited States, Canada
-
ExelixisCompletedRenal Cell Carcinoma | Papillary Thyroid Cancer | Follicular Thyroid Cancer | Huerthle Cell Thyroid CancerUnited States
-
ExelixisCompletedGastrointestinal Neoplasms | Gastrointestinal Stromal TumorsUnited States
-
ExelixisCompletedLymphoma | Cancer | Thyroid CarcinomaUnited States
-
ExelixisApproved for marketing
-
ExelixisCompletedMelanoma | Cancer | Colorectal Cancer | Non-small-cell Lung Cancer | Papillary Thyroid CancerUnited States
-
ExelixisTerminatedMyeloproliferative Disorders | Polycythemia Vera | Thrombocythemia, Essential | MyelofibrosisUnited States
-
ExelixisTerminatedChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
ERAS Turkey AssociationRecruitingCoronary Artery Disease | Iron Deficiency AnemiaTurkey
-
ExelixisRecruitingColorectal CancerUnited States, Poland, Australia, Belgium, France, Hong Kong, Korea, Republic of, Spain, Hungary, Singapore, New Zealand, Germany, Thailand, Taiwan, Portugal, United Kingdom
-
ExelixisCompletedCancer | Solid TumorsUnited States, Taiwan, Belgium, Israel, United Kingdom
-
ExelixisActive, not recruitingTriple Negative Breast Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm MalignantUnited States